Marina Biotech, Mirna deal

The companies partnered to develop microRNA-based targeted cancer therapies using Marina's SMARTICLES liposomal-based delivery technology and Mirna's miRNAs. Marina is eligible to receive up to $63 million total in upfront and milestone payments, as well as royalties. Mirna will be responsible for the development and commercialization of resulting products, while Marina will provide support for preclinical and process development. Details were not disclosed. ...